首页 > 最新文献

Revista espanola de medicina nuclear e imagen molecular最新文献

英文 中文
Increased rates of [18F]FDG accumulation in the brain in children could lead to a lower amount of [18F]FDG reaching other organs and tumors: Is a new SUV correction factor that considers [18F]FDG uptake of the brain in children necessary? 儿童脑内[18F]FDG蓄积率的增加可能导致[18F]FDG到达其他器官和肿瘤的量减少:是否需要一种新的SUV校正因子来考虑儿童脑内[18F]FDG的摄取?
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500123
Ebru Tatcı , Seval Beykan Schuerrle , Özlem Özmen

Objective

[18F]FDG uptake in the livers and tumors of children is lower than that of adults. The brain exhibits intense physiological [18F]FDG uptake. In childhood, the ratio of brain weight to body height and the ratio of brain weight to body weight are higher than those of adults. We hypothesized that in children, most of the [18F]FDG would be retained in the brain, resulting in less [18F]FDG activity reaching other organs and tumor tissues.

Methods

The [18F]FDG PET/CT images of 56 pediatric and 24 adult patients were evaluated retrospectively. Patients were divided into four age groups: 1) 3–7 years old, 2) 8–12 years old, 3) 13–17 years old, and 4) over 18 years old. Accumulated [18F]FDG activity in the brain, liver, and whole body (WB) was calculated using the manually drawn volumes of interest for all patients using NUKDOS software. Also, SUV normalized to total body weight (SUVbw) and SUV normalized to lean body mass (SUVlbm) of the liver were calculated using the NUKDOS software.

Results

The mean [18F]FDG accumulation ratio of brain-to-WB was significantly higher in patients aged 3−7 years and 8−12 years than in adults. Brain/WB [18F]FDG activity ratio was lower in the 13−17 age group compared to the 3−7 age group (P = .0001). The accumulated [18F]FDG activity ratio of liver-to-WB in the 3−7 age group was significantly lower than in adults when comparing the four groups (P = .0001). The mean of liver SUVbw was statistically lower in the 3−7 and 8−12 age groups than in the 13−17 and adult groups. Patients aged 3−7 years had a significantly lower mean liver SUVlbm than those in the other age groups. The mean liver SUVlbm was also significantly lower in the 8−12 years and 13−17 years age groups than in adults. There was a negative correlation between blood glucose levels and the amount of [18F]FDG in the brain. However, no statistically significant correlation existed between blood glucose and age.

Conclusion

We showed that the [18F]FDG accumulation rate was higher in the brain and lower in the liver in the children when compared to adults. Our findings suggest that increased uptake of [18F]FDG in children's brains may lead to reduced activity reaching other organs and tumor tissue. To improve diagnostic accuracy, adapted SUV correction protocols can be developed for pediatric populations, considering age-related changes in [18F]FDG uptake ratio of the brain.
目的:[18F]儿童FDG在肝脏和肿瘤中的摄取低于成人。大脑表现出强烈的生理[18F]FDG摄取。儿童期脑重与身高之比、脑重与体重之比均高于成人。我们假设,在儿童中,大部分[18F]FDG将保留在大脑中,导致较少的[18F]FDG活性到达其他器官和肿瘤组织。方法:回顾性分析56例儿童和24例成人患者的FDG /CT影像。患者分为4个年龄组:1)3-7岁,2)8-12岁,3)13-17岁,4)18岁以上。使用NUKDOS软件对所有患者手工绘制感兴趣体积,计算脑、肝和全身(WB)累积[18F]FDG活性。采用NUKDOS软件计算肝脏SUV归一化至总体重(SUVbw)和SUV归一化至瘦体重(SUVlbm)。结果:3-7岁和8-12岁患者脑脑FDG / wb平均[18F]积累比明显高于成人。13-17岁年龄组的脑/脑[18F]FDG活性比低于3-7岁年龄组(P = .0001)。4组比较,3 ~ 7岁组肝脏与wb累积[18F]FDG活性比显著低于成人(P = .0001)。3-7岁和8-12岁年龄组的肝脏SUVbw平均值低于13-17岁和成人组。3-7岁患者的平均肝脏SUVlbm明显低于其他年龄组。8-12岁和13-17岁年龄组的平均肝脏SUVlbm也明显低于成人。血糖水平与脑内[18F]FDG含量呈负相关。然而,血糖与年龄之间没有统计学上的显著相关性。结论:我们发现,与成人相比,儿童的[18F]FDG在大脑中的积累率更高,在肝脏中的积累率更低。我们的研究结果表明,儿童大脑中[18F]FDG摄取的增加可能导致到达其他器官和肿瘤组织的活动减少。为了提高诊断的准确性,可以针对儿科人群制定适应性的SUV校正方案,同时考虑脑[18F]FDG摄取比的年龄相关变化。
{"title":"Increased rates of [18F]FDG accumulation in the brain in children could lead to a lower amount of [18F]FDG reaching other organs and tumors: Is a new SUV correction factor that considers [18F]FDG uptake of the brain in children necessary?","authors":"Ebru Tatcı ,&nbsp;Seval Beykan Schuerrle ,&nbsp;Özlem Özmen","doi":"10.1016/j.remnie.2025.500123","DOIUrl":"10.1016/j.remnie.2025.500123","url":null,"abstract":"<div><h3>Objective</h3><div>[<sup>18</sup><span>F]FDG uptake in the livers and tumors of children is lower than that of adults. The brain exhibits intense physiological [</span><sup>18</sup><span>F]FDG uptake. In childhood, the ratio of brain weight to body height and the ratio of brain weight to body weight are higher than those of adults. We hypothesized that in children, most of the [</span><sup>18</sup>F]FDG would be retained in the brain, resulting in less [<sup>18</sup>F]FDG activity reaching other organs and tumor tissues.</div></div><div><h3>Methods</h3><div>The [<sup>18</sup><span>F]FDG PET/CT images of 56 pediatric and 24 adult patients were evaluated retrospectively. Patients were divided into four age groups: 1) 3–7 years old, 2) 8–12 years old, 3) 13–17 years old, and 4) over 18 years old. Accumulated [</span><sup>18</sup><span><span><span>F]FDG activity in the brain, liver, and whole body (WB) was calculated using the manually drawn volumes of interest for all patients using NUKDOS software. Also, SUV normalized to total </span>body weight (SUVbw) and SUV normalized to </span>lean body mass (SUVlbm) of the liver were calculated using the NUKDOS software.</span></div></div><div><h3>Results</h3><div>The mean [<sup>18</sup>F]FDG accumulation ratio of brain-to-WB was significantly higher in patients aged 3−7 years and 8−12 years than in adults. Brain/WB [<sup>18</sup>F]FDG activity ratio was lower in the 13−17 age group compared to the 3−7 age group (<em>P</em> = .0001). The accumulated [<sup>18</sup>F]FDG activity ratio of liver-to-WB in the 3−7 age group was significantly lower than in adults when comparing the four groups (<em>P</em><span> = .0001). The mean of liver SUVbw was statistically lower in the 3−7 and 8−12 age groups than in the 13−17 and adult groups. Patients aged 3−7 years had a significantly lower mean liver SUVlbm than those in the other age groups. The mean liver SUVlbm was also significantly lower in the 8−12 years and 13−17 years age groups than in adults. There was a negative correlation between blood glucose levels and the amount of [</span><sup>18</sup><span>F]FDG in the brain. However, no statistically significant correlation existed between blood glucose and age.</span></div></div><div><h3>Conclusion</h3><div>We showed that the [<sup>18</sup>F]FDG accumulation rate was higher in the brain and lower in the liver in the children when compared to adults. Our findings suggest that increased uptake of [<sup>18</sup>F]FDG in children's brains may lead to reduced activity reaching other organs and tumor tissue. To improve diagnostic accuracy, adapted SUV correction protocols can be developed for pediatric populations, considering age-related changes in [<sup>18</sup>F]FDG uptake ratio of the brain.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500123"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semi-quantitative MIBG scores in relapsed/refractory neuroblastoma: Prognostic insights from post-131I-MIBG treatment scans and impact of SPECT-CT imaging 复发/难治性神经母细胞瘤的半定量MIBG评分:131i -MIBG治疗扫描和SPECT-CT成像影响的预后见解
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500133
M.E. Mavi , P. Özgen-Kıratlı , A. Varan , B. Volkan-Salancı

Objectives

Neuroblastoma often demonstrates high uptake of MIBG, which is used for imaging and therapy. This retrospective observational study aimed to assess the prognostic significance of modified Curie scores (mCS) and SIOPEN scores (SS) derived from post-treatment 131I-MIBG scans in relapsed/refractory neuroblastoma. Additionally, the impact of SPECT-CT imaging on these scores was investigated as a secondary goal.

Material and methods

Pediatric patients with relapsed/refractory neuroblastoma, who underwent 131I-MIBG treatment, were included (n = 35). mCS and SS were calculated from planar images of post-treatment 131I-MIBG scans. Patients were then categorized based on the cut-off values obtained from these scans, and survival analysis was conducted. To investigate the impact of SPECT-CT imaging on scores, mCS and SS were also calculated from both planar and SPECT-CT images of diagnostic 123I-MIBG scans separately.

Results

Patients with mCS>12 or SS > 23 on post-treatment 131I-MIBG scans had significantly worse overall survival. mCS and SS from SPECT-CT were significantly higher than planar images in pre- and post-treatment diagnostic 123I-MIBG scans. SPECT-CT caused changes in mCS for 61% and SS for 55% of patients, predominantly in axial and appendicular skeleton regions.

Conclusions

Both mCS and SS from post-treatment 131I-MIBG planar scans correlated significantly with overall survival in relapsed/refractory neuroblastoma. Patients with mCS>12 or SS > 23 had poorer survival. SPECT-CT imaging influenced scores for a substantial portion of patients, emphasizing its value alongside planar imaging. Larger, comprehensive studies are warranted to validate these findings and refine prognostic cut-offs. Incorporating SPECT-CT in relevant body regions is recommended for improved disease assessment.
目的:神经母细胞瘤通常表现为MIBG的高摄取,用于成像和治疗。这项回顾性观察性研究旨在评估治疗后131I-MIBG扫描得出的改良Curie评分(mCS)和SIOPEN评分(SS)对复发/难治性神经母细胞瘤的预后意义。此外,SPECT-CT成像对这些评分的影响作为次要目标进行了研究。材料和方法:纳入接受131I-MIBG治疗的复发/难治性神经母细胞瘤儿童患者(n = 35)。从处理后的131I-MIBG扫描平面图像计算mCS和SS。然后根据这些扫描获得的临界值对患者进行分类,并进行生存分析。为了研究SPECT-CT成像对评分的影响,我们还分别从诊断性123I-MIBG扫描的平面和SPECT-CT图像中计算mCS和SS。结果:在治疗后的131I-MIBG扫描中,mCS >2或SS bbb23患者的总生存期明显较差。在治疗前和治疗后的123I-MIBG诊断扫描中,SPECT-CT的mCS和SS明显高于平面图像。SPECT-CT导致61%的患者mCS改变,55%的患者SS改变,主要发生在轴向和附肢骨骼区域。结论:治疗后131I-MIBG平面扫描的mCS和SS与复发/难治性神经母细胞瘤的总生存率显著相关。mCS >2或SS bbb23患者的生存期较差。SPECT-CT成像影响了相当一部分患者的评分,强调了其与平面成像的价值。有必要进行更大规模、更全面的研究来验证这些发现,并完善预后临界值。建议在相关身体区域结合SPECT-CT以改进疾病评估。
{"title":"Semi-quantitative MIBG scores in relapsed/refractory neuroblastoma: Prognostic insights from post-131I-MIBG treatment scans and impact of SPECT-CT imaging","authors":"M.E. Mavi ,&nbsp;P. Özgen-Kıratlı ,&nbsp;A. Varan ,&nbsp;B. Volkan-Salancı","doi":"10.1016/j.remnie.2025.500133","DOIUrl":"10.1016/j.remnie.2025.500133","url":null,"abstract":"<div><h3>Objectives</h3><div><span>Neuroblastoma often demonstrates high uptake of MIBG, which is used for imaging and therapy. This retrospective observational study aimed to assess the prognostic significance of modified Curie scores (mCS) and SIOPEN scores (SS) derived from post-treatment </span><sup>131</sup>I-MIBG scans in relapsed/refractory neuroblastoma. Additionally, the impact of SPECT-CT imaging on these scores was investigated as a secondary goal.</div></div><div><h3>Material and methods</h3><div>Pediatric patients with relapsed/refractory neuroblastoma, who underwent <sup>131</sup>I-MIBG treatment, were included (n<!--> <!-->=<!--> <!-->35). mCS and SS were calculated from planar images of post-treatment <sup>131</sup>I-MIBG scans. Patients were then categorized based on the cut-off values obtained from these scans, and survival analysis was conducted. To investigate the impact of SPECT-CT imaging on scores, mCS and SS were also calculated from both planar and SPECT-CT images of diagnostic <sup>123</sup>I-MIBG scans separately.</div></div><div><h3>Results</h3><div>Patients with mCS&gt;12 or SS<!--> <!-->&gt;<!--> <!-->23 on post-treatment <sup>131</sup>I-MIBG scans had significantly worse overall survival. mCS and SS from SPECT-CT were significantly higher than planar images in pre- and post-treatment diagnostic <sup>123</sup><span>I-MIBG scans. SPECT-CT caused changes in mCS for 61% and SS for 55% of patients, predominantly in axial and appendicular skeleton regions.</span></div></div><div><h3>Conclusions</h3><div>Both mCS and SS from post-treatment <sup>131</sup>I-MIBG planar scans correlated significantly with overall survival in relapsed/refractory neuroblastoma. Patients with mCS&gt;12 or SS<!--> <!-->&gt;<!--> <!-->23 had poorer survival. SPECT-CT imaging influenced scores for a substantial portion of patients, emphasizing its value alongside planar imaging. Larger, comprehensive studies are warranted to validate these findings and refine prognostic cut-offs. Incorporating SPECT-CT in relevant body regions is recommended for improved disease assessment.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500133"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contribution of 123-I in Peritoneal Strumosis 123-I在腹膜瘘中的作用。
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500200
L. Delgado Niño , J. Romero Martínez , F. Martín Ordoñez
{"title":"Contribution of 123-I in Peritoneal Strumosis","authors":"L. Delgado Niño ,&nbsp;J. Romero Martínez ,&nbsp;F. Martín Ordoñez","doi":"10.1016/j.remnie.2025.500200","DOIUrl":"10.1016/j.remnie.2025.500200","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500200"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET/CT in breast cancer 乳腺癌的PET/CT。
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500139
J.F. Bastidas , M. Martínez de Bourio-Allona , A. Roteta Unceta Barrenechea , M. Rodríguez-Fraile , L. Sancho
Breast cancer is one of the most prevalent neoplasms worldwide, with molecular subtypes that influence prognosis and therapeutic strategies. PET/CT with different radiopharmaceuticals has revolutionized diagnosis, staging, and treatment monitoring. [18F]-Fluorodeoxyglucose remains the most widely used radiotracer, but it has limitations in certain subtypes, such as invasive lobular carcinoma, where 16α-[18F] fluoro-17β-estradiol and [68Ga]-FAPI (fibroblast activation protein inhibitors) have demonstrated greater utility. Today, HER2-targeted radiopharmaceuticals, such as [89Zr]-trastuzumab, allow for a precise assessment of tumor heterogeneity. PET/CT also plays a key role in detecting bone metastases using [18F]-NaF and in identifying new therapeutic targets, such as PSMA (prostate-specific membrane antigen) and GRPR (gastrin-releasing peptide receptor). These advancements establish molecular imaging as an essential tool for personalizing breast cancer treatment, optimizing clinical decision-making, and improving diagnostic accuracy.
乳腺癌是世界范围内最常见的肿瘤之一,其分子亚型影响预后和治疗策略。PET/CT与不同的放射性药物已经彻底改变了诊断,分期和治疗监测。[18F]-氟脱氧葡萄糖仍然是最广泛使用的放射性示踪剂,但它在某些亚型中有局限性,例如浸润性小叶癌,其中16α-[18F]氟-17β-雌二醇和[68Ga]- fapi(成纤维细胞活化蛋白抑制剂)显示出更大的效用。如今,靶向her2的放射性药物,如[89Zr]-曲妥珠单抗,可以精确评估肿瘤异质性。PET/CT在使用[18F]-NaF检测骨转移以及发现新的治疗靶点(如前列腺特异性膜抗原PSMA和胃泌素释放肽受体GRPR)方面也发挥着关键作用。这些进步使分子成像成为个性化乳腺癌治疗、优化临床决策和提高诊断准确性的重要工具。
{"title":"PET/CT in breast cancer","authors":"J.F. Bastidas ,&nbsp;M. Martínez de Bourio-Allona ,&nbsp;A. Roteta Unceta Barrenechea ,&nbsp;M. Rodríguez-Fraile ,&nbsp;L. Sancho","doi":"10.1016/j.remnie.2025.500139","DOIUrl":"10.1016/j.remnie.2025.500139","url":null,"abstract":"<div><div>Breast cancer is one of the most prevalent neoplasms worldwide, with molecular subtypes that influence prognosis and therapeutic strategies. PET/CT with different radiopharmaceuticals has revolutionized diagnosis, staging, and treatment monitoring. [<sup>18</sup>F]-Fluorodeoxyglucose remains the most widely used radiotracer, but it has limitations in certain subtypes, such as invasive lobular carcinoma, where 16α-[<sup>18</sup>F] fluoro-17β-estradiol and [<sup>68</sup>Ga]-FAPI (fibroblast activation protein inhibitors) have demonstrated greater utility. Today, HER2-targeted radiopharmaceuticals, such as [<sup>89</sup>Zr]-trastuzumab, allow for a precise assessment of tumor heterogeneity. PET/CT also plays a key role in detecting bone metastases using [<sup>18</sup>F]-NaF and in identifying new therapeutic targets, such as PSMA (prostate-specific membrane antigen) and GRPR (gastrin-releasing peptide receptor). These advancements establish molecular imaging as an essential tool for personalizing breast cancer treatment, optimizing clinical decision-making, and improving diagnostic accuracy.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500139"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SPECT/CT with 99mTc-sestamibi in the diagnosis of renal masses 99mTc-sestamibi对肾肿块的SPECT/CT诊断价值。
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500197
L. Pinilla, E. Riera, J.R. García, L.I. Mont-Castro, M. Soria, E. Valls
{"title":"SPECT/CT with 99mTc-sestamibi in the diagnosis of renal masses","authors":"L. Pinilla,&nbsp;E. Riera,&nbsp;J.R. García,&nbsp;L.I. Mont-Castro,&nbsp;M. Soria,&nbsp;E. Valls","doi":"10.1016/j.remnie.2025.500197","DOIUrl":"10.1016/j.remnie.2025.500197","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500197"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical course and features of thyroid oncocytic (Hurthle cell) cancer: Comparison with thyroid follicular cancer 甲状腺嗜瘤细胞癌(Hurthle细胞)的临床过程和特点:与甲状腺滤泡癌比较。
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500158
K. Okuyucu , U.M. Turan , P. Akkus Gunduz , M. Ozkara , N. Aydinbelge Dizdar , A. Cinar , M. Samsum , P. Sahin Oguz , R.D. Zeyrek , N. Ersoz Gulcelik , S. Ince

Introduction and objectives

Although, oncocytic (Hurthle cell) carcinoma (OTC) resembles to follicular thyroid carcinoma (FTC), they are different tumors derived from thyroid follicular cells. OTC comprises 3–5% of all differentiated thyroid carcinomas and has more aggressive behaviour than FTC. Clinicians discuss about the treatment and prognosis of OTC. We evaluated its clinicopathological features and clinical course.

Material and methods

We examined and followed up 169 patients with OTC (126 minimally invasive, 43 widely invasive) and 837 patients with FTC (640 minimally invasive, 197 widely invasive). OTC and FTC were compared according to prognostic variables, recurrence rate (Rec) and outcome. The predictor factors impacting on recurrence in OTC were also determined.

Results

There were statistically significant differences between OTC and FTC in age, sex, capsule invasion (CI), tumor size (TS), total administered [131I]NaI dose (TID), stimulated thyroglobulin (sTg), Rec and stage (p < 0.001, p = 0.032, p < 0.001, p < 0.001, p = 0.004, p = 0.026, p = 0.017, p = 0.044, respectively). Age, CI, extrathyroidal extension (ETE), TS, initial lymph node metastasis (ILNM), sTg and stage (p = 0.01, p = 0.016, p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001, respectively) were the predictors for recurrence in OTC. Metastasis incidence was 19.5% for OTC and 12% for FTC. The cause of death was cancer in 25 patients with FTC (2.8%) and 11 patients with OTC (6.5%).

Conclusion

The prognosis of minimally invasive OTC is quite favorable. However the prognosis of widely invasive OTC is unfavorable. RAI may be administered to these tumors, but it is in vain to insist on RAI after the first adjuvant therapy if it does not respond.
简介和目的:虽然嗜瘤细胞(Hurthle细胞)癌(OTC)与滤泡性甲状腺癌(FTC)相似,但它们是源于甲状腺滤泡细胞的不同肿瘤。OTC占所有分化型甲状腺癌的3-5%,比FTC更具侵袭性。临床医生讨论OTC的治疗和预后。我们评估其临床病理特征和临床病程。材料与方法:对169例OTC患者(微创126例,广泛侵入43例)和837例FTC患者(微创640例,广泛侵入197例)进行检查与随访。根据预后变量、复发率(Rec)和转归对OTC和FTC进行比较。同时确定了影响OTC复发的预测因素。结果:OTC与FTC患者在年龄、性别、囊膜侵袭(CI)、肿瘤大小(TS)、总给药[131I]NaI剂量(TID)、促甲状腺球蛋白(sTg)、Rec、分期等方面差异均有统计学意义(p)。然而,广泛侵袭的OTC预后不佳。这些肿瘤可以使用RAI,但在第一次辅助治疗后如果没有反应,坚持RAI是徒劳的。
{"title":"Clinical course and features of thyroid oncocytic (Hurthle cell) cancer: Comparison with thyroid follicular cancer","authors":"K. Okuyucu ,&nbsp;U.M. Turan ,&nbsp;P. Akkus Gunduz ,&nbsp;M. Ozkara ,&nbsp;N. Aydinbelge Dizdar ,&nbsp;A. Cinar ,&nbsp;M. Samsum ,&nbsp;P. Sahin Oguz ,&nbsp;R.D. Zeyrek ,&nbsp;N. Ersoz Gulcelik ,&nbsp;S. Ince","doi":"10.1016/j.remnie.2025.500158","DOIUrl":"10.1016/j.remnie.2025.500158","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Although, oncocytic (Hurthle cell) carcinoma (OTC) resembles to follicular thyroid carcinoma (FTC), they are different tumors derived from thyroid follicular cells. OTC comprises 3–5% of all differentiated thyroid carcinomas and has more aggressive behaviour than FTC. Clinicians discuss about the treatment and prognosis of OTC. We evaluated its clinicopathological features and clinical course.</div></div><div><h3>Material and methods</h3><div>We examined and followed up 169 patients with OTC (126 minimally invasive, 43 widely invasive) and 837 patients with FTC (640 minimally invasive, 197 widely invasive). OTC and FTC were compared according to prognostic variables, recurrence rate (Rec) and outcome. The predictor factors impacting on recurrence in OTC were also determined.</div></div><div><h3>Results</h3><div>There were statistically significant differences between OTC and FTC in age, sex, capsule invasion (CI), tumor size (TS), total administered [131I]NaI dose (TID), stimulated thyroglobulin (sTg), Rec and stage (p<!--> <!-->&lt;<!--> <!-->0.001, p<!--> <!-->=<!--> <!-->0.032, p<!--> <!-->&lt;<!--> <!-->0.001, p<!--> <!-->&lt;<!--> <!-->0.001, p<!--> <!-->=<!--> <!-->0.004, p<!--> <!-->=<!--> <!-->0.026, p<!--> <!-->=<!--> <!-->0.017, p<!--> <!-->=<!--> <!-->0.044, respectively). Age, CI, extrathyroidal extension (ETE), TS, initial lymph node metastasis (ILNM), sTg and stage (p<!--> <!-->=<!--> <!-->0.01, p<!--> <!-->=<!--> <!-->0.016, p<!--> <!-->&lt;<!--> <!-->0.001, p<!--> <!-->&lt;<!--> <!-->0.001, p<!--> <!-->&lt;<!--> <!-->0.001, p<!--> <!-->&lt;<!--> <!-->0.001, p<!--> <!-->&lt;<!--> <!-->0.001, respectively) were the predictors for recurrence in OTC. Metastasis incidence was 19.5% for OTC and 12% for FTC. The cause of death was cancer in 25 patients with FTC (2.8%) and 11 patients with OTC (6.5%).</div></div><div><h3>Conclusion</h3><div>The prognosis of minimally invasive OTC is quite favorable. However the prognosis of widely invasive OTC is unfavorable. RAI may be administered to these tumors, but it is in vain to insist on RAI after the first adjuvant therapy if it does not respond.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500158"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Response to the letter regarding “Evaluating the Role of Sarcopenia and [18F]FDG PET/CT Parameters in Prognosis of Pancreatic Ductal Adenocarcinoma” 回复:关于“评估肌少症及[18F]FDG PET/CT参数在胰腺导管腺癌预后中的作用”的回复。
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500164
H. Önner, M.N. Calderon-Tobar, L. Perktaş, F. Yilmaz, G. Kara Gedіk
{"title":"Re: Response to the letter regarding “Evaluating the Role of Sarcopenia and [18F]FDG PET/CT Parameters in Prognosis of Pancreatic Ductal Adenocarcinoma”","authors":"H. Önner,&nbsp;M.N. Calderon-Tobar,&nbsp;L. Perktaş,&nbsp;F. Yilmaz,&nbsp;G. Kara Gedіk","doi":"10.1016/j.remnie.2025.500164","DOIUrl":"10.1016/j.remnie.2025.500164","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500164"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of thyroid/background ratio in distinguishing Graves’ disease from subacute thyroiditis: A comparative study 甲状腺/背景比值鉴别格雷夫斯病与亚急性甲状腺炎诊断准确性的比较研究
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500199
G. Silov , F. Bati , N. Biçakçi , B. Kirtiloğlu , M. Yilmaz

Background and objective

Thyrotoxicosis is a common clinical condition in endocrinology, with Graves’ disease (GD) and subacute thyroiditis (SAT) as its predominant causes. These disorders often share overlapping clinical and biochemical features, making differential diagnosis challenging. This study evaluates the diagnostic efficacy of the thyroid/background ratio (TBR) as a semiquantitative method for differentiating GD from SAT and compares multiple diagnostic parameters.

Materials and methods

This was a retrospective analysis of 106 consecutive patients newly diagnosed with thyrotoxicosis. All participants underwent assessment of free tri-iodothyronine (fT3), free thyroxine (fT4), TSH, thyroid-stimulating immunoglobulin (TSI), Anti-TPO, Anti-Tg, CRP, erythrocyte sedimentation rate (ESR), 99mTc thyroid scintigraphy (TS), and ultrasonography (USG). TBR was calculated from TS. Each patient was followed for at least six months, with final diagnoses of GD or SAT made by an endocrinologist.

Results

Sixty-eight and 38 patients were diagnosed with GD and SAT, respectively. The analysis of thyroid-associated laboratory markers and inflammatory indices revealed characteristic differences between GD and SAT. Multivariable logistic regression analysis revealed three independent predictors of SAT: diminished TSI (OR = 0.04; P = .039), reduced fT3/fT4 ratio (OR = 0.05, P = .019), and lower TBR (OR = 0.20, P = .001). TSI demonstrated high diagnostic accuracy area under the curve (AUC): 0.923, optimal cut-off: ≤1.05 IU/L, sensitivity: 100%, specificity: 85.9%). The TBR yielded the highest AUC (0.990) in distinguishing GD from SAT (cut-off: ≤3.6 IU/L, sensitivity: 97.4%, specificity: 98.5%).
According to USG findings, the cases showed two different patterns as diffuse thyroiditis pattern (DTP) and nodular thyroiditis pattern (NTP). On USG a DTP was more frequent in GD group than in SAT group (80.9% vs. 55.3%, P = .007). In both GD and SAT, demographic and clinical findings were similar between patients with DTP and patients with NTP. However, symptom duration, TSI, fT3, fT3/fT4 ratio, anti-TPO, thyroid ROI and TBR levels were higher in GD patients with DTP or NTP than in SAT patients with DTP or NTP. In contrast, background ROI, ESR and CRP levels were lower. Among patients with DTP, a TBR cut-off value of ≤3.7 yielded a sensitivity of 95.2% and a specificity of 98.2% in distinguishing SAT from GD. In this cohort, TBR demonstrated superior diagnostic performance compared to TSI. The optimal TBR threshold for differentiating SAT from GD among patients with NTP was <2.3, exhibiting 100% sensitivity and 100% specificity. However, the diagnostic performance was not significantly different from that of TSI. A positive thyroglossal duct activity finding was present only in GD, in 45.5% of the patients.

Conclusion<

背景与目的:甲状腺毒症是内分泌科常见的临床疾病,以Graves病(GD)和亚急性甲状腺炎(SAT)为主要病因。这些疾病通常具有重叠的临床和生化特征,使得鉴别诊断具有挑战性。本研究评估了甲状腺/背景比(TBR)作为区分GD和SAT的半定量方法的诊断效果,并比较了多个诊断参数。材料和方法:回顾性分析106例连续新诊断为甲状腺毒症的患者。所有参与者均接受游离三碘甲状腺原氨酸(fT3)、游离甲状腺素(fT4)、TSH、促甲状腺免疫球蛋白(TSI)、抗tpo、抗tg、CRP、红细胞沉降率(ESR)、99mtc甲状腺显像(TS)和超声检查(USG)的评估。TBR由TS计算。每位患者至少随访6个月,最终由内分泌学家诊断为GD或SAT。结果:GD患者68例,SAT患者38例。甲状腺相关实验室标志物和炎症指标分析显示GD和SAT之间存在特征性差异。多变量logistic回归分析显示了SAT的三个独立预测因素:TSI降低(OR = 0.04;p = 0.039),减少发生/ fT4比率(或= 0.05,p = 0.019),并降低为(或= 0.20,p = 0.001)。TSI具有较高的诊断准确率,曲线下面积(AUC)为0.923,最佳截止值≤1.05 IU/L,灵敏度为100%,特异性为85.9%。TBR鉴别GD和SAT的AUC最高(0.990)(截止值≤3.6 IU/L,敏感性97.4%,特异性98.5%)。根据USG检查结果,病例表现为弥漫性甲状腺炎(DTP)和结节性甲状腺炎(NTP)两种不同的模式。在USG中,GD组DTP发生率高于SAT组(80.9%比55.3%,p = 0.007)。在GD和SAT中,DTP患者和NTP患者的人口学和临床结果相似。GD合并DTP或NTP患者的症状持续时间、TSI、fT3、fT3/fT4比值、抗tpo、甲状腺ROI和TBR水平均高于SAT合并DTP或NTP患者。相比之下,背景ROI、ESR和CRP水平较低。在DTP患者中,TBR临界值≤3.7,区分SAT和GD的敏感性为95.2%,特异性为98.2%。在这个队列中,与TSI相比,TBR表现出更好的诊断性能。结论:fT3/fT4比值作为区分GD和SAT的诊断工具的有效性有限。TSI具有较高的准确性,但TBR在区分SAT和GD方面的诊断准确性最高(AUC: 0.990)。根据亚组分析,DTP病例TBR的诊断准确率高于TSI,而NTP病例TBR的诊断准确率与TSI相当。
{"title":"Diagnostic accuracy of thyroid/background ratio in distinguishing Graves’ disease from subacute thyroiditis: A comparative study","authors":"G. Silov ,&nbsp;F. Bati ,&nbsp;N. Biçakçi ,&nbsp;B. Kirtiloğlu ,&nbsp;M. Yilmaz","doi":"10.1016/j.remnie.2025.500199","DOIUrl":"10.1016/j.remnie.2025.500199","url":null,"abstract":"<div><h3>Background and objective</h3><div>Thyrotoxicosis is a common clinical condition in endocrinology, with Graves’ disease (GD) and subacute thyroiditis (SAT) as its predominant causes. These disorders often share overlapping clinical and biochemical features, making differential diagnosis challenging. This study evaluates the diagnostic efficacy of the thyroid/background ratio (TBR) as a semiquantitative method for differentiating GD from SAT and compares multiple diagnostic parameters.</div></div><div><h3>Materials and methods</h3><div>This was a retrospective analysis of 106 consecutive patients newly diagnosed with thyrotoxicosis. All participants underwent assessment of free tri-iodothyronine (fT3), free thyroxine (fT4), TSH, thyroid-stimulating immunoglobulin (TSI), Anti-TPO, Anti-Tg, CRP, erythrocyte sedimentation rate (ESR), 99mTc thyroid scintigraphy (TS), and ultrasonography (USG). TBR was calculated from TS. Each patient was followed for at least six months, with final diagnoses of GD or SAT made by an endocrinologist.</div></div><div><h3>Results</h3><div>Sixty-eight and 38 patients were diagnosed with GD and SAT, respectively. The analysis of thyroid-associated laboratory markers and inflammatory indices revealed characteristic differences between GD and SAT. Multivariable logistic regression analysis revealed three independent predictors of SAT: diminished TSI (OR = 0.04; <em>P</em> = .039), reduced fT3/fT4 ratio (OR = 0.05, <em>P</em> = .019), and lower TBR (OR = 0.20, <em>P</em> = .001). TSI demonstrated high diagnostic accuracy area under the curve (AUC): 0.923, optimal cut-off: ≤1.05 IU/L, sensitivity: 100%, specificity: 85.9%). The TBR yielded the highest AUC (0.990) in distinguishing GD from SAT (cut-off: ≤3.6 IU/L, sensitivity: 97.4%, specificity: 98.5%).</div><div>According to USG findings, the cases showed two different patterns as diffuse thyroiditis pattern (DTP) and nodular thyroiditis pattern (NTP). On USG a DTP was more frequent in GD group than in SAT group (80.9% <em>vs</em>. 55.3%, <em>P</em> = .007). In both GD and SAT, demographic and clinical findings were similar between patients with DTP and patients with NTP. However, symptom duration, TSI, fT3, fT3/fT4 ratio, anti-TPO, thyroid ROI and TBR levels were higher in GD patients with DTP or NTP than in SAT patients with DTP or NTP. In contrast, background ROI, ESR and CRP levels were lower. Among patients with DTP, a TBR cut-off value of ≤3.7 yielded a sensitivity of 95.2% and a specificity of 98.2% in distinguishing SAT from GD. In this cohort, TBR demonstrated superior diagnostic performance compared to TSI. The optimal TBR threshold for differentiating SAT from GD among patients with NTP was &lt;2.3, exhibiting 100% sensitivity and 100% specificity. However, the diagnostic performance was not significantly different from that of TSI. A positive thyroglossal duct activity finding was present only in GD, in 45.5% of the patients.</div></div><div><h3>Conclusion<","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500199"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of 99mTc-HYNIC-PSMA-11, bone scan and post radioligand therapy images in mCRPC patients: A single center experience mCRPC患者99mTc-HYNIC-PSMA-11、骨扫描和放射治疗后图像的比较:单中心经验
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500157
K. Aryana , A. Aghaee , E. Askari , Y. Fakhar , N. Raeisi , M. Mottaghi , M. Emadzadeh , H. Ghorbani , S. Barashki

Background

Prostate-Specific Membrane Antigen is overexpressed in primary and metastatic prostate cancer tissues. While PSMA PET agents have gained their role in the prostate cancer guidelines, Technetium-based PSMA agents have left behind. Given the novelty of 99mTc-HYNIC-PSMA-11, we conducted this study to compare its detection rate in tracing skeletal metastases in comparison to bone scans and also compared the number of metastatic lesions which showed PSMA uptake in the diagnostic scan with those detected in post-treatment scans after radioligand therapy (RLT) with 177Lu-PSMA-617-617.

Methods

Bone and 99mTc-HYNIC-PSMA-11 scans with a maximum interval of 90 days were performed in thirty-nine patients with widespread bone metastases. If the PSMA scan was positive, patients were treated with 177Lu-PSMA-617 and post treatment scan was also obtained. For negative PSMA results, 68Ga-PSMA PET/CT was performed to compare its results with the bone scan. In patients with PSMA expression, detection of metastatic lesions in three consecutive whole-body scans in different regions were compared (99mTc-HYNIC-PSMA-11 with bone and post treatment scans, separately).

Results

37 (94.9%) showed adequate 99mTc-HYNIC-PSMA-11 uptake in the metastatic regions. Compared to bone scan, 99mTc-HYNIC-PSMA-11 showed additional lesions in 13 (35.1%) participants which were mostly located in the appendicular skeleton and pelvic bones. Inversely, the bone scan detected more lesions in 12 (32.4%) patients. Both scans in 12 (32.4%) patients showed the exact same results. Comparison between the 99mTc-HYNIC-PSMA-11 scan and 177Lu-PSMA-617 showed completely similar results in 29 (78.4%) patients; however, 177Lu-PSMA-617 detected more lesions in eight (21.6%) participants.

Conclusion

The 99mTc-HYNIC-PSMA-11 scan demonstrates comparable results to bone scans in evaluating skeletal metastases in prostate cancer patients. It serves as a cost-effective modality for identifying suitable candidates for radioligand therapy, particularly beneficial in resource-limited countries.
背景:前列腺特异性膜抗原在原发性和转移性前列腺癌组织中过表达。虽然PSMA PET制剂已经在前列腺癌指南中发挥了作用,但基于锝的PSMA制剂却落在了后面。鉴于99mtc - hylic -PSMA-11的新颖性,我们进行了这项研究,比较了它在追踪骨骼转移方面的检出率与骨扫描的比较,并比较了在诊断扫描中显示PSMA摄取的转移病灶数量与使用177Lu-PSMA-617-617放射配体治疗(RLT)后的治疗后扫描中发现的转移病灶数量。方法:对39例广泛骨转移患者进行骨和99mTc-HYNIC-PSMA-11扫描,最长间隔为90天。如果PSMA扫描呈阳性,则患者接受177Lu-PSMA-617治疗,并获得治疗后扫描。对于PSMA阴性结果,进行68Ga-PSMA PET/CT与骨扫描结果进行比较。在PSMA表达的患者中,比较了连续三次全身扫描在不同区域的转移病灶检测(99mTc-HYNIC-PSMA-11分别与骨扫描和治疗后扫描)。结果:37例(94.9%)在转移区显示99mTc-HYNIC-PSMA-11摄取充足。与骨扫描相比,99mTc-HYNIC-PSMA-11在13名(35.1%)参与者中显示额外的病变,主要位于阑尾骨骼和骨盆骨。相反,在12例(32.4%)患者中,骨扫描检测到更多病变。12例(32.4%)患者的两次扫描结果完全相同。99mTc-HYNIC-PSMA-11扫描与177Lu-PSMA-617的比较显示,29例(78.4%)患者的结果完全相似;然而,177Lu-PSMA-617在8名(21.6%)参与者中检测到更多病变。结论:99mTc-HYNIC-PSMA-11扫描在评估前列腺癌患者骨骼转移方面的结果与骨扫描相当。它是一种具有成本效益的方式,用于确定放射治疗的合适候选人,在资源有限的国家特别有益。
{"title":"Comparison of 99mTc-HYNIC-PSMA-11, bone scan and post radioligand therapy images in mCRPC patients: A single center experience","authors":"K. Aryana ,&nbsp;A. Aghaee ,&nbsp;E. Askari ,&nbsp;Y. Fakhar ,&nbsp;N. Raeisi ,&nbsp;M. Mottaghi ,&nbsp;M. Emadzadeh ,&nbsp;H. Ghorbani ,&nbsp;S. Barashki","doi":"10.1016/j.remnie.2025.500157","DOIUrl":"10.1016/j.remnie.2025.500157","url":null,"abstract":"<div><h3>Background</h3><div><span>Prostate-Specific Membrane Antigen is overexpressed in primary and metastatic prostate cancer<span> tissues. While PSMA PET agents have gained their role in the prostate cancer guidelines, Technetium-based PSMA agents have left behind. Given the novelty of </span></span><sup>99m</sup><span><span>Tc-HYNIC-PSMA-11, we conducted this study to compare its detection rate in tracing skeletal metastases<span> in comparison to bone scans and also compared the number of metastatic lesions which showed PSMA uptake in the diagnostic scan with those detected in post-treatment scans after </span></span>radioligand therapy (RLT) with </span><sup>177</sup>Lu-PSMA-617-617.</div></div><div><h3>Methods</h3><div>Bone and <sup>99m</sup>Tc-HYNIC-PSMA-11 scans with a maximum interval of 90 days were performed in thirty-nine patients with widespread bone metastases. If the PSMA scan was positive, patients were treated with <sup>177</sup>Lu-PSMA-617 and post treatment scan was also obtained. For negative PSMA results, <sup>68</sup><span>Ga-PSMA PET/CT was performed to compare its results with the bone scan. In patients with PSMA expression, detection of metastatic lesions in three consecutive whole-body scans in different regions were compared (</span><sup>99m</sup>Tc-HYNIC-PSMA-11 with bone and post treatment scans, separately).</div></div><div><h3>Results</h3><div>37 (94.9%) showed adequate <sup>99m</sup>Tc-HYNIC-PSMA-11 uptake in the metastatic regions. Compared to bone scan, <sup>99m</sup><span>Tc-HYNIC-PSMA-11 showed additional lesions in 13 (35.1%) participants which were mostly located in the appendicular skeleton and pelvic bones. Inversely, the bone scan detected more lesions in 12 (32.4%) patients. Both scans in 12 (32.4%) patients showed the exact same results. Comparison between the </span><sup>99m</sup>Tc-HYNIC-PSMA-11 scan and <sup>177</sup>Lu-PSMA-617 showed completely similar results in 29 (78.4%) patients; however, <sup>177</sup>Lu-PSMA-617 detected more lesions in eight (21.6%) participants.</div></div><div><h3>Conclusion</h3><div>The <sup>99m</sup><span><span>Tc-HYNIC-PSMA-11 scan demonstrates comparable results to bone scans in evaluating skeletal metastases in prostate cancer patients. It serves as a cost-effective modality for identifying suitable candidates for </span>radioligand therapy, particularly beneficial in resource-limited countries.</span></div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500157"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Staging in nasopharynx cancers prognostic value of volumetric parameters in [18F]FDG PET/CT imaging [18F]FDG PET/CT成像中体积参数对鼻咽癌分期的预后价值。
Pub Date : 2025-11-01 DOI: 10.1016/j.remnie.2025.500160
Ç. Erol , Ö. Şahin , G. Kanyılmaz , S. Erol

Objective

The aim of our study was to determine whether volumetric parameters measured from the primary lesion and metastatic lymph node (LN) using [18F]FDG PET/CT imaging affect prognosis and survival in nasopharyngeal cancer (NPC) patients.

Material and methods

Our study included 62 patients diagnosed with NPC who underwent [18F]FDG PET/CT imaging for pre-treatment staging. SUVmax, SUVmean, MTV and TLG values were measured from the primary tumor and LN. Lymph node/primary tumor SUV ratio (NTR) was calculated. The relationships between volumetric parameters and overall survival (OS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated.

Results

LN SUVmax and LN SUVmean values were significantly higher in patients with distant metastases (p = 0.002 and p = 0.016, respectively). NTR values were significantly higher in patients with distant metastases (p = 0.047). The ideal LN SUVmax and SUVmean cut-off values for predicting distant metastasis in patients with LN metastasis were 16.45 and 6.5, respectively. There was a statistically significant difference between the DMFSs of the two groups when the NTR cut-off value was 0.8 (p = 0.047). Multivariate analysis showed that LN SUVmax, LN SUVmean and NTR were associated with DMFS (P = 0.003, 0.05 and 0.014, respectively), while primary tumor TLG and MTV values were associated with LRRFS (P = 0.035 and 0.03, respectively).

Conclusion

In conclusion, we believe that LN SUVmax, SUVmean and NTR may be prognostic indicators for distant metastasis, and MTV and TLG for locoregional recurrence.
目的:我们研究的目的是确定使用[18F]FDG PET/CT成像从原发病变和转移淋巴结(LN)测量的体积参数是否影响鼻咽癌(NPC)患者的预后和生存。材料和方法:我们的研究纳入了62例诊断为鼻咽癌的患者,他们接受了[18F]FDG PET/CT成像进行治疗前分期。从原发肿瘤和淋巴结测量SUVmax、SUVmean、MTV和TLG值。计算淋巴结/原发肿瘤SUV比(NTR)。评估容积参数与总生存期(OS)、局部无复发生存期(LRRFS)、远处无转移生存期(DMFS)和无进展生存期(PFS)之间的关系。结果:LN SUVmax和LN SUVmean在远处转移患者中显著升高(p = 0.002和p = 0.016)。远处转移患者的NTR值显著高于其他患者(p = 0.047)。预测LN转移患者远处转移的理想SUVmax和SUVmean临界值分别为16.45和6.5。NTR截断值为0.8时,两组患者dmfs差异有统计学意义(p = 0.047)。多因素分析显示,LN SUVmax、LN SUVmean、NTR与DMFS相关(P分别为0.003、0.05、0.014),原发肿瘤TLG、MTV值与LRRFS相关(P分别为0.035、0.03)。结论:总之,我们认为LN SUVmax、SUVmean和NTR可能是远处转移的预后指标,MTV和TLG可能是局部复发的预后指标。
{"title":"Staging in nasopharynx cancers prognostic value of volumetric parameters in [18F]FDG PET/CT imaging","authors":"Ç. Erol ,&nbsp;Ö. Şahin ,&nbsp;G. Kanyılmaz ,&nbsp;S. Erol","doi":"10.1016/j.remnie.2025.500160","DOIUrl":"10.1016/j.remnie.2025.500160","url":null,"abstract":"<div><h3>Objective</h3><div><span>The aim of our study was to determine whether volumetric parameters measured from the primary lesion and metastatic lymph node (LN) using [</span><sup>18</sup><span>F]FDG PET/CT imaging affect prognosis and survival in nasopharyngeal cancer (NPC) patients.</span></div></div><div><h3>Material and methods</h3><div>Our study included 62 patients diagnosed with NPC who underwent [<sup>18</sup><span><span>F]FDG PET/CT imaging for pre-treatment staging. SUVmax, SUVmean, MTV and TLG values were measured from the primary tumor<span> and LN. Lymph node/primary tumor SUV ratio (NTR) was calculated. The relationships between volumetric parameters and </span></span>overall survival (OS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) were evaluated.</span></div></div><div><h3>Results</h3><div>LN SUVmax and LN SUVmean values were significantly higher in patients with distant metastases<span><span> (p = 0.002 and p = 0.016, respectively). NTR values were significantly higher in patients with distant metastases (p = 0.047). The ideal LN SUVmax and SUVmean cut-off values for predicting distant metastasis in patients with LN metastasis were 16.45 and 6.5, respectively. There was a statistically significant difference between the DMFSs of the two groups when the NTR cut-off value was 0.8 (p = 0.047). </span>Multivariate analysis showed that LN SUVmax, LN SUVmean and NTR were associated with DMFS (P = 0.003, 0.05 and 0.014, respectively), while primary tumor TLG and MTV values were associated with LRRFS (P = 0.035 and 0.03, respectively).</span></div></div><div><h3>Conclusion</h3><div>In conclusion, we believe that LN SUVmax, SUVmean and NTR may be prognostic indicators for distant metastasis, and MTV and TLG for locoregional recurrence.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 6","pages":"Article 500160"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista espanola de medicina nuclear e imagen molecular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1